lurasidone

Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study

Authors: Robert Goldman, Antony Loebel, Josephine Cucchiaro, Ling Deng, Robert L Findling

Journal: Journal of Child and Adolescent Psychopharmacology

Year Published: 2017

Objective: To evaluate the efficacy and safety of lurasidone in acutely symptomatic adolescent patients with schizophrenia. Methods: Patients aged 13-17 years were randomly assigned to 6 weeks of double-blind, fixed-dose lurasidone (40 or 80 mg/day) or […]

Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia

Authors: Brian J Miller, Andrei Pikalov, Cynthia O Siu, Michael Tocco, Joyce Tsai, Philip D Harvey, John W Newcomer, Antony Loebel

Journal: Comprehensive Psychiatry

Year Published: 2020

Background: Accumulating evidence has implicated insulin resistance and inflammation in the pathophysiology of cognitive impairments associated with neuropsychiatric disorders. This post-hoc analysis based on a placebo-controlled trial investigated the effect of inflammation (indexed by CRP) and […]

C-reactive protein and response to lurasidone treatment in children and adolescents with bipolar I depression: Results from a placebo-controlled trial

Authors: Charles L. Raison, Cynthia Siu, Andrei Pikalov, Michael Tocco, Antony Loebel

Journal: Brain Behavior and Immunity

Year Published: 2019

This study sought to investigate associations between levels of high-sensitivity c-reactive protein (hsCRP) prior to treatment and change in depressive symptoms and cognition in a short-term, double-blind, placebo-controlled study of lurasidone in children and adolescents with […]

Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia

Authors: Philip D Harvey, Cynthia O Siu, Antony D Loebel

Journal: Schizophrenia Research: Cognition

Year Published: 2017

Daytime sleepiness is a commonly reported adverse effect associated with psychotropic agents that may impair cognitive performance and functioning. The objective of this post-hoc analysis was to evaluate the long-term effects of lurasidone and quetiapine XR […]

Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension

Authors: Philip D Harvey, Cynthia O Siu, Jay Hsu, Josephine Cucchiaro, Paul Maruff, Antony Loebel

Journal: European Neuropsychopharmacology

Year Published: 2013

This double-blind study evaluated change in cognitive performance and functional capacity in lurasidone and quetiapine XR-treated schizophrenia patients over a 6-week, placebo-controlled study, followed by a 6-month, double-blind extension. Cognitive performance and functional capacity were assessed […]

Back to Publications